These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 38973542

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The combination of fecal calprotectin with ESR, CRP and albumin discriminates more accurately children with Crohn's disease.
    Daniluk U, Daniluk J, Krasnodebska M, Lotowska JM, Sobaniec-Lotowska ME, Lebensztejn DM.
    Adv Med Sci; 2019 Mar; 64(1):9-14. PubMed ID: 30237086
    [Abstract] [Full Text] [Related]

  • 3. Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease.
    Mak LY, Tong TSM, Cheung KS, Chen LJ, Lui KL, Lau KS, Leung WK.
    Clin Transl Gastroenterol; 2020 Mar; 11(3):e00138. PubMed ID: 32132451
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The use of serum calprotectin as a biomarker for inflammatory activity in inflammatory bowel disease.
    Suárez Ferrer C, Abadía Barno M, Martín Arranz E, Jochems A, García Ramírez L, Poza Cordón J, Jaquotot Herranz M, Cerpa Arencibia A, Martín Arranz MD.
    Rev Esp Enferm Dig; 2019 Oct; 111(10):744-749. PubMed ID: 31476872
    [Abstract] [Full Text] [Related]

  • 8. [Application of chosen granulocyte markers in diagnostics of Leśniowski-Crohn's disease and ulcerative colitis--preliminary research].
    Fedak D, Pawlica D, Ciećko-Michalska I, Solnica B, Mach T.
    Przegl Lek; 2010 Oct; 67(2):114-8. PubMed ID: 20557011
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM, Liu T, Gao S, Tong XD, Deng FH, Nie B.
    World J Gastroenterol; 2017 Dec 14; 23(46):8235-8247. PubMed ID: 29290660
    [Abstract] [Full Text] [Related]

  • 10. Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization.
    Fukunaga S, Kuwaki K, Mitsuyama K, Takedatsu H, Yoshioka S, Yamasaki H, Yamauchi R, Mori A, Kakuma T, Tsuruta O, Torimura T.
    Int J Mol Med; 2018 Jan 14; 41(1):107-118. PubMed ID: 29115397
    [Abstract] [Full Text] [Related]

  • 11. Correlation Between Serum and Fecal Biomarkers and Patient-Reported Outcomes in Patients with Crohn's Disease and Ulcerative Colitis.
    Motwani KK, Alizadeh M, Abutaleb A, Grossman J, Wellington J, Cross RK, SPARC-IBD investigators.
    Dig Dis Sci; 2024 Jun 14; 69(6):2154-2163. PubMed ID: 38580888
    [Abstract] [Full Text] [Related]

  • 12. Seasonal variability of vitamin D status in patients with inflammatory bowel disease - A retrospective cohort study.
    Janssen CE, Globig AM, Busse Grawitz A, Bettinger D, Hasselblatt P.
    PLoS One; 2019 Jun 14; 14(5):e0217238. PubMed ID: 31120977
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease.
    Mori A, Mitsuyama K, Sakemi R, Yoshioka S, Fukunaga S, Kuwaki K, Yamauchi R, Araki T, Yoshimura T, Yamasaki H, Tsuruta K, Morita T, Yamasaki S, Tsuruta O, Torimura T.
    Kurume Med J; 2021 Dec 15; 66(4):209-215. PubMed ID: 34690210
    [Abstract] [Full Text] [Related]

  • 14. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
    Henriksen M, Jahnsen J, Lygren I, Stray N, Sauar J, Vatn MH, Moum B, IBSEN Study Group.
    Gut; 2008 Nov 15; 57(11):1518-23. PubMed ID: 18566104
    [Abstract] [Full Text] [Related]

  • 15. Disease monitoring in inflammatory bowel disease.
    Chang S, Malter L, Hudesman D.
    World J Gastroenterol; 2015 Oct 28; 21(40):11246-59. PubMed ID: 26523100
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.
    Ricanek P, Brackmann S, Perminow G, Lyckander LG, Sponheim J, Holme O, Høie O, Rydning A, Vatn MH, IBSEN II Study Group.
    Scand J Gastroenterol; 2011 Sep 28; 46(9):1081-91. PubMed ID: 21619483
    [Abstract] [Full Text] [Related]

  • 17. Higher vitamin D serum concentration increases health related quality of life in patients with inflammatory bowel diseases.
    Hlavaty T, Krajcovicova A, Koller T, Toth J, Nevidanska M, Huorka M, Payer J.
    World J Gastroenterol; 2014 Nov 14; 20(42):15787-96. PubMed ID: 25400464
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease.
    Shimoyama T, Yamamoto T, Yoshiyama S, Nishikawa R, Umegae S.
    Inflamm Bowel Dis; 2023 Sep 01; 29(9):1399-1408. PubMed ID: 36334015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.